Italian Cohort: Olive Oil Linked to Lower Cancer, CV and All-Cause Mortality

This 13-year prospective cohort study of 22,892 Italian adults from the Moli-sani Study, published in the European Journal of Clinical Nutrition, found that higher olive oil consumption was associated with 20% lower all-cause mortality, 25% lower cardiovascular mortality, and 23% lower cancer mortality. The associations held independent of overall Mediterranean diet score and were only partially mediated by conventional cardiometabolic risk biomarkers -- suggesting additional biological pathways remain to be characterized.

Why This Study Matters

PREDIMED is Spanish. CORDIOPREV is Spanish. The Harvard cohort studies are American. The Italian olive oil literature -- despite Italy being one of the world's largest olive oil producers and consumers -- has been less robust in large prospective cohorts. Moli-sani fills that gap. The study tracked 22,892 adults from the Molise region of southern Italy, with detailed dietary assessment, 13.1 years of follow-up, and adjudicated mortality endpoints.

Equally important: the Moli-sani analysis is one of the few studies to formally investigate which biomarkers mediate the olive-oil-to-mortality association. The authors examined whether inflammatory, metabolic, cardiovascular, and renal biomarkers explained the observed reduction in mortality risk. According to PubMed, the paper was published in European Journal of Clinical Nutrition on May 4, 2024 (DOI: 10.1038/s41430-024-01442-8).

The result was a meaningful but partial mediation. The investigated biomarkers explained 21.2% of the all-cause mortality association and 13.7% of the cancer mortality association. That leaves roughly 80% of the all-cause effect and 86% of the cancer effect unexplained by conventional measures -- a clue that olive oil's biological influence extends beyond the standard cardiometabolic risk panel.

How It Was Designed

The basics are in the study design bar above: 22,892 men and women, 13.1-year median follow-up, southern Italian (Molise region) cohort, 188-item validated food frequency questionnaire.

Olive oil intake was standardized to a 10-gram tablespoon size and categorized into intake brackets ranging from 1.5 tablespoons per day or less (low) to more than 3 tablespoons per day (high). The 188-item FFQ was administered at baseline (2005-2010) and validated against multiple-day food records and biomarker measures. Overall diet quality was scored using a Mediterranean diet score independent of the olive oil intake variable -- so that adjustment for diet quality reflects the rest of the diet pattern, not the olive oil itself.

Multivariable Cox proportional-hazards models adjusted for age, sex, education, smoking status, physical activity, BMI, total energy intake, hypertension, dyslipidemia, type 2 diabetes, history of cancer, and -- in the headline model -- overall Mediterranean diet score. The diet-quality adjustment is the key methodological move: it tests whether olive oil's effect survives once you account for the surrounding Mediterranean dietary context.

The team also conducted change-in-estimate mediation analyses by sequentially adding inflammatory biomarkers (CRP, white blood cell count, neutrophil/lymphocyte ratio), metabolic biomarkers (fasting glucose, HOMA-IR, triglycerides), cardiovascular biomarkers (blood pressure, LDL, HDL), and renal biomarkers (eGFR, creatinine) to the Cox model. The percentage attenuation in the hazard ratio after adding each set of biomarkers estimates how much of the olive-oil-to-mortality association each biological pathway might be carrying.

What They Found

Comparing high olive oil consumers (more than 3 tablespoons per day) to low consumers (1.5 tablespoons per day or less), after adjusting for diet quality and the full covariate set:

Outcome	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
All-cause mortality	0.80 (0.69-0.94)	20% lower	Death from any cause
Cancer mortality	0.77 (0.59-0.99)	23% lower	Death from any cancer
Cardiovascular mortality	0.75 (0.58-0.97)	25% lower	Heart disease, stroke, other CVD
Other-cause mortality	0.97 (0.73-1.29)	Not significant	Non-cancer, non-CVD deaths

Green indicates a favorable direction vs. low olive oil intake (1.5 tablespoons per day or less). The all-cause, cancer, and cardiovascular hazard ratios are statistically significant; 95% confidence intervals exclude 1.0. The other-cause hazard ratio is not statistically significant.

In the mediation analyses, the investigated cardiometabolic biomarkers attenuated the all-cause mortality association by 21.2% and the cancer mortality association by 13.7%. The remaining unexplained association -- roughly 80% of the all-cause effect and 86% of the cancer effect -- points to biological pathways beyond the conventional cardiometabolic panel.

Reading the Results

The independence from diet quality. The Moli-sani analysis adjusted for the overall Mediterranean diet score and the olive oil association still held. That is the key methodological insight from this paper: olive oil's effect is not simply a marker for the rest of the Mediterranean diet. It carries an independent signal even within an Italian population whose overall dietary pattern is already Mediterranean. The same pattern was reported in the 2024 Tessier JAMA Network Open dementia paper from the Harvard cohorts -- olive oil's effect held across diet quality tiers.

The cancer signal. A 23% reduction in cancer mortality is one of the larger cancer-specific associations reported for olive oil in the literature. The 2022 Harvard paper (Guasch-Ferre, JACC) reported a 17% reduction. The plausible mechanisms include anti-inflammatory effects of olive polyphenols, modulation of insulin-like growth factors, and direct effects of phenolic compounds on cancer cell signaling. The PREDIMED secondary analyses showed lower breast cancer incidence with the EVOO arm. The Moli-sani finding strengthens the case for a cancer-specific component of olive oil's mortality association.

The mediation gap. The biomarker mediation analysis is the most novel piece of this paper. Conventional cardiometabolic risk factors (inflammation, glucose regulation, lipid panel, blood pressure, kidney function) explained 21.2% of the all-cause mortality association. That leaves 78.8% unexplained. The implication is that olive oil exerts biological effects that are not fully captured by the standard cardiometabolic risk panel. Candidate pathways include direct antioxidant effects on tissues, gut microbiome modulation, anti-inflammatory effects beyond CRP, autophagy induction, and effects on cellular senescence -- none of which were measured in the Moli-sani biomarker set.

The dose threshold. The benefit emerged at intake above 3 tablespoons per day (more than 30 g/day). This is higher than the threshold identified in the U.S. Harvard cohorts (more than 7 g/day) but lower than typical PREDIMED intake (approximately 45 to 50 g/day). The cross-study pattern suggests a dose-response continuum: modest benefits at U.S.-typical intake, larger benefits at Mediterranean-typical intake.

What Didn't Change

The other-cause mortality category (non-cancer, non-cardiovascular deaths) showed no significant association with olive oil intake (HR 0.97; 95% CI 0.73 to 1.29). This is a useful null finding -- it suggests the mortality benefit is concentrated in cardiovascular and cancer endpoints rather than spread evenly across all causes of death. That specificity is mechanistically reassuring.

The study is observational. Despite the diet quality adjustment and the extensive covariate set, residual confounding by socioeconomic factors, health-conscious behavior patterns, or unmeasured dietary components cannot be excluded. PREDIMED and CORDIOPREV -- both RCTs -- provide the experimental complement to this observational evidence.

Generalizability is also constrained. The cohort is drawn from a single Italian region (Molise), with culturally entrenched olive oil consumption and a Mediterranean dietary backdrop. Whether the dose-response curve holds at the higher intake levels in non-Mediterranean populations is precisely the question that the Harvard cohort studies have been answering.

Broader Context

Moli-sani is the largest non-PREDIMED Italian olive oil cohort to date. It replicates, in an Italian population, the all-cause and cause-specific mortality findings reported in the U.S. Harvard cohorts (Guasch-Ferre 2020 JACC; Guasch-Ferre 2022 JACC; Tessier 2024 JAMA Network Open) and the within-PREDIMED dose-response findings (Guasch-Ferre 2014 BMC Medicine). The cross-cohort consistency across Spanish RCT, Spanish PREDIMED secondary analysis, Italian observational, and U.S. observational evidence is one of the strongest patterns in the entire nutrition literature.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg/day of hydroxytyrosol and derivatives. The Moli-sani mediation analysis is interesting in this context: conventional cardiometabolic biomarkers (including lipid measures) explained only a fraction of the mortality association, suggesting the EFSA-authorized lipid-oxidation mechanism is a real but not exhaustive description of olive oil's biological footprint.

PREDIMED (Estruch et al., NEJM 2018 republished) provides the randomized-trial backbone of this literature: 31% reduction in major cardiovascular events with a Mediterranean diet supplemented with EVOO. CORDIOPREV (Delgado-Lista et al., The Lancet 2022) extended the finding to secondary prevention. The Moli-sani paper sits in the observational layer alongside the Harvard cohort studies, replicating their findings in a distinct Italian population.

Related Research

Continue exploring olive oil and polyphenol science:

• Olive Oil and 19% Lower Mortality in 92,383 U.S. Adults Over 28 Years
• Olive Oil and Cardiovascular Risk in U.S. Adults: The JACC 2020 Cohort

Source: View the original study on PubMed

Olivea's Dosage

The Moli-sani benefit emerged at intake above 3 tablespoons per day (more than 30 g/day) of olive oil. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams. Three tablespoons per day delivers approximately 42 grams, comfortably above the Moli-sani threshold. For a concentrated polyphenol dose without the caloric load, each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.